AUTL Stock: Autolus Therapeutics plc Stock Price, Analysis & Insights
Get live AUTL stock price $1.50, comprehensive Autolus Therapeutics plc stock analysis, charts, news, and expert forecast. Real-time AUTL stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene auto...
Company Information
- CEO
- Christian Martin Itin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 647
Contact Information
- Website
- https://www.autolus.com
- Address
- The MediaWorks
- Country
- GB
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 2.01)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Autolus Therapeutics plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Autolus Therapeutics plc
- ⚠Investors should consider how Autolus Therapeutics plc fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
397.88M
P/E Ratio (TTM)
-1.37
Beta
2.01
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare AUTL with peer companies:
- Price
- $1.15
- Market cap
- 146.27M
- Price
- $5.24
- Market cap
- 626.63M
- Price
- $6.33
- Market cap
- 406.06M
- Price
- $10.78
- Market cap
- 282.90M
- Price
- $30.08
- Market cap
- 862.59M
- Price
- $1.65
- Market cap
- 304.79M
- Price
- $1.01
- Market cap
- 198.81M
- Price
- $58.01
- Market cap
- 959.26M
- Price
- $2.68
- Market cap
- 292.64M
- Price
- $6.77
- Market cap
- 527.62M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.